Scarica l'app Stockscreener
27.80
2.96%
0.80
Dopo l'orario di chiusura:
28.00
0.20
+0.72%
Precedente Chiudi:
$27.00
Aprire:
$27.3
Volume 24 ore:
752.79K
Relative Volume:
0.76
Capitalizzazione di mercato:
$2.07B
Reddito:
$97.36M
Utile/perdita netta:
$-172.42M
Rapporto P/E:
-12.10
EPS:
-2.2984
Flusso di cassa netto:
$-188.84M
1 W Prestazione:
+19.11%
1M Prestazione:
+35.94%
6M Prestazione:
+143.65%
1 anno Prestazione:
+273.66%
Intervallo 1D:
$27.07
$28.16
Intervallo di 1 settimana:
$22.79
$28.16
Portata 52W:
$7.50
$28.16
Xencor Inc Stock (XNCR) Company Profile
Nome
Xencor Inc
Settore
Industria
Telefono
626-305-5900
Indirizzo
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
27.80 | 2.01B | 97.36M | -172.42M | -188.84M | -2.2984 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-24 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-10-29 | Aggiornamento | Barclays | Underweight → Overweight |
| 2025-09-17 | Ripresa | Barclays | Underweight |
| 2025-09-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-04-21 | Iniziato | William Blair | Outperform |
| 2024-12-12 | Iniziato | Wells Fargo | Overweight |
| 2024-12-02 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-04-16 | Reiterato | BTIG Research | Buy |
| 2024-02-28 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-05-19 | Iniziato | BofA Securities | Buy |
| 2022-12-06 | Iniziato | Cowen | Outperform |
| 2022-10-13 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2022-09-21 | Iniziato | JP Morgan | Overweight |
| 2022-07-06 | Ripresa | Canaccord Genuity | Buy |
| 2022-02-11 | Iniziato | BMO Capital Markets | Outperform |
| 2022-01-21 | Iniziato | SMBC Nikko | Outperform |
| 2021-12-15 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2021-02-24 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-03-04 | Iniziato | Barclays | Underweight |
| 2020-02-25 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-01-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-11-20 | Ripresa | Guggenheim | Neutral |
| 2019-08-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-08-07 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2019-06-13 | Iniziato | Mizuho | Buy |
| 2019-04-12 | Iniziato | Guggenheim | Buy |
| 2019-03-27 | Iniziato | Berenberg | Buy |
| 2019-03-15 | Iniziato | Raymond James | Outperform |
| 2018-09-10 | Ripresa | BTIG Research | Buy |
| 2018-03-28 | Ripresa | Leerink Partners | Outperform |
| 2017-03-02 | Iniziato | Instinet | Neutral |
| 2017-03-02 | Reiterato | Wedbush | Outperform |
| 2016-10-04 | Iniziato | Piper Jaffray | Overweight |
| 2015-12-22 | Iniziato | Canaccord Genuity | Buy |
| 2015-08-05 | Reiterato | MLV & Co | Buy |
| 2015-02-12 | Reiterato | Oppenheimer | Outperform |
| 2015-01-28 | Reiterato | MLV & Co | Buy |
| 2014-07-11 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Xencor Inc Borsa (XNCR) Ultime notizie
103,736 Shares in Xencor, Inc. $XNCR Bought by DCF Advisers LLC - MarketBeat
Xencor stock hits 52-week high at 26.18 USD - Investing.com
A Quick Look at Today's Ratings for Xencor(XNCR.US), With a Forecast Between $20 to $44 - Moomoo
Xencor (NASDAQ:XNCR) Hits A Fresh High: What Comes Next? - Kalkine Media
Xencor (NASDAQ:XNCR) Sets New 52-Week HighShould You Buy? - MarketBeat
Do Xencor’s (XNCR) Mixed 2026 Loss Trends Hint at Shifting Cost Discipline? - simplywall.st
Johnson & Johnson Purchases New Shares in Xencor, Inc. $XNCR - MarketBeat
Industry Analysts Just Made A Huge Upgrade To Their Xencor, Inc. (NASDAQ:XNCR) Revenue Forecasts - simplywall.st
Analysts' Revenue Estimates For Xencor, Inc. (NASDAQ:XNCR) Are Surging Higher - Moomoo
(XNCR) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Biotech Stocks At 52-Week HighsBIVI +22%, XNCR, ANRO, HAE, ACAD - RTTNews
Xencor (NASDAQ:XNCR) Hits New 1-Year HighHere's What Happened - MarketBeat
XNCR Q2 2026 Earnings: Narrower-Than-Expected Loss Drives 4.89% Share UptickFree Cash Flow Trends - vinanet.vn
Xencor stock hits 52-week high at 21.99 USD By Investing.com - Investing.com Canada
Xencor stock hits 52-week high at 21.99 USD - Investing.com
Xencor Inc (XNCR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cantor Fitzgerald Maintains Xencor(XNCR.US) With Buy Rating, Maintains Target Price $44 - Moomoo
Analysts Are Upgrading Xencor, Inc. (NASDAQ:XNCR) After Its Latest Results - webull.com
How Investors May Respond To Xencor (XNCR) Narrowing Quarterly Losses Amid Deeper First‑Half Deficit - Yahoo Finance
BofA Securities Maintains Xencor(XNCR.US) With Hold Rating, Raises Target Price to $20 - Moomoo
Xencor (NASDAQ:XNCR) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Xencor Inc (XNCR) Stock News Today - TradingKey
Xencor, Inc. Stock 12‑Month Price Target Raised to $29, Implies 45% Upside - TradingView
Xencor, Inc. (XNCR) Stock Report: A Biotech Innovator With 40.83% Upside Potential - DirectorsTalk Interviews
Barclays Reaffirms Their Buy Rating on Xencor (XNCR) - theglobeandmail.com
Xencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of "Hold" by Brokerages - marketbeat.com
Xencor: Q2 Earnings Snapshot - AOL.com
Cantor Fitzgerald Maintains Xencor(XNCR.US) With Buy Rating, Raises Target Price to $44 - Moomoo
XENCOR Maintains Outperform Rating -- Price Target Raised to $20 - GuruFocus
Truist Financial Maintains Xencor(XNCR.US) With Buy Rating - Moomoo
Xencor Reports Fourth Quarter and Full Year 2025 Financial Results - The National Law Review
Wedbush Maintains Xencor(XNCR.US) With Buy Rating, Raises Target Price to $30 - Moomoo
Xencor (NASDAQ:XNCR) Surges: What Comes Next? - Kalkine Media
Does Xencor’s Mixed 2026 Loss Trend Reshape the Investment Narrative Around XNCR’s R&D Priorities? - simplywall.st
Xencor (NASDAQ:XNCR) Price Target Raised to $30.00 - MarketBeat
Xencor (NASDAQ:XNCR) Hits New 52-Week High Following Better-Than-Expected Earnings - marketbeat.com
Wedbush Adjusts Price Target on Xencor to $30 From $26, Maintains Outperform Rating - marketscreener.com
RBC Capital Adjusts PT on Xencor to $20 From $19, Maintains Outperform Speculative Risk Rating - marketscreener.com
Xencor (NASDAQ:XNCR) Price Target Raised to $44.00 at Cantor Fitzgerald - marketbeat.com
Xencor, Inc. Stock 12‑Month Price Target Raised to $28.5, Implies 44% Upside - TradingView
Xencor Inc (XNCR) SWOT Analysis: Financial Challenges and Strate - GuruFocus
Xencor Inc earnings beat by $0.51, revenue topped estimates - Investing.com
Xencor, Inc. (XNCR) Stock Forecasts - Yahoo! Finance Canada
Xencor (NASDAQ:XNCR) Releases Earnings Results, Beats Expectations By $0.51 EPS - MarketBeat
Xencor, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Xencor (XNCR) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
XENCOR ($XNCR) Releases Q2 2026 Earnings - Quiver Quantitative
Biopharma firm Xencor's Q2 revenue beats on royalty revenue, milestone payments - TradingView
Xencor Inc 2Q 2026: Revenue $51.22M, EPS ($0.29) — 10-Q Summary - TradingView
Xencor (NASDAQ: XNCR) nets $105M Alexion settlement as Q2 2026 loss hits $21.7M - Stock Titan
Xencor reports Q2 2026 revenue $51.2M, net loss $21.7M; cash $486.4M - TradingView
Xencor Inc Azioni (XNCR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.21%
1.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):